Harnessing the Activity of Targeted Therapy in HER2-Mutant NSCLC

Joshua K. Sabari, MD, discusses key considerations when testing for HER2 alterations in non–small cell lung cancer

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

Zosia Piotrowska, MD, MHS, discusses disease factors that guide treatment decision-making and sequencing for patients with HER2-mutated NSCLC.

Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.

Nicolas Girard, MD, discusses both de novo and acquired resistance alterations in HER2-altered non–small cell lung cancer.

Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.